Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Breast Cancer

Free Subscription Articles published in JAMA Retrieve available abstracts of 50 articles: HTML format

Single Articles

April 2026
1. ESSERMAN LJ, Olopade OI, Eklund M
   Screening for Breast Cancer-Reply.
   JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1269.
   PubMed    
   
   
   
2. PESAPANE F, Cassano E
   Screening for Breast Cancer.
   JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1263.
   PubMed    
   
   
   
3. SMIT F, Kaufman JS, Chiolero A
   Screening for Breast Cancer.
   JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1266.
   PubMed    
   
   
   February 2026
4. PLEASANT V, Ring K
   What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors.
   JAMA. 2026 Feb 5. doi: 10.1001/jama.2026.0025.
   PubMed    
   
   
   December 2025
5. 
   Risk-Based vs Annual Breast Cancer Screening: Research Summary.
   JAMA. 2025 Dec 12:e2524865. doi: 10.1001/jama.2025.24865.
   PubMed    
   
   
   
6. ESSERMAN LJ, Fiscalini AS, Naeim A, Van't Veer LJ, et al
   Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
   JAMA. 2025 Dec 12:e2524784. doi: 10.1001/jama.2025.24784.
   PubMed     Abstract available
   
   
   
7. BAXTER NN, Phillips KA
   Unlocking the Potential of Risk-Based Screening for Breast Cancer: From Detection to Prevention.
   JAMA. 2025 Dec 12. doi: 10.1001/jama.2025.24817.
   PubMed    
   
   
   October 2025
8. PANT S
   Lesser-Known Lobular Breast Cancer on the Rise.
   JAMA. 2025 Oct 24. doi: 10.1001/jama.2025.17524.
   PubMed    
   
   
   April 2025
9. FAN L, Shao ZM
   Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
   JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1294.
   PubMed    
   
   
   
10. PEI YY
    Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer.
    JAMA. 2025 Apr 23. doi: 10.1001/jama.2025.1291.
    PubMed    
    
    
    March 2025
11. HWANG ES, Hyslop T, Lynch T, Ryser MD, et al
    Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
    JAMA. 2025;333:972-980.
    PubMed     Abstract available
    
    
    
12. ANDERER S
    Trial: Less Frequent Mammograms Pose No Greater Risk After Breast Cancer.
    JAMA. 2025 Mar 7. doi: 10.1001/jama.2025.1346.
    PubMed    
    
    
    
13. LIM WH
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27807.
    PubMed    
    
    
    
14. WESTHOFF CL, Pike MC, Pearce CL
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27795.
    PubMed    
    
    
    
15. LUO P, Lin A, Miao K
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27804.
    PubMed    
    
    
    
16. SLOTH MMB, Jorgensen TSH, Nybo Andersen AM
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27798.
    PubMed    
    
    
    
17. LIBERTY AL, Rodriguez MI, Edelman A
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27810.
    PubMed    
    
    
    
18. MORCH LS, Meaidi A, Corn G
    Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems-Reply.
    JAMA. 2025 Mar 3. doi: 10.1001/jama.2024.27801.
    PubMed    
    
    
    January 2025
19. HUNTER N, Hurvitz S
    Where Did the Passion Go?-Rethinking Adjuvant Immune Therapy for Triple-Negative Breast Cancer.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26811.
    PubMed    
    
    
    
20. IGNATIADIS M, Bailey A, McArthur H, El-Abed S, et al
    Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
    JAMA. 2025 Jan 30. doi: 10.1001/jama.2024.26886.
    PubMed     Abstract available
    
    
    December 2024
21. JOENSUU H
    Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.25927.
    PubMed    
    
    
    
22. CHEN L, Li H, Zhang H, Yang H, et al
    Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.
    JAMA. 2024 Dec 13. doi: 10.1001/jama.2024.23560.
    PubMed     Abstract available
    
    
    November 2024
23. ANDERER S
    ACOG Now Recommends Breast Cancer Screenings Start at Age 40.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23048.
    PubMed    
    
    
    
24. ANDERER S
    Study: BMI May Underestimate Obesity-Linked Breast Cancer Risk.
    JAMA. 2024 Nov 15. doi: 10.1001/jama.2024.23049.
    PubMed    
    
    
    
25. ORRALL A
    Breast Cancer Incidence Still Rising Despite Decline in Death Rates.
    JAMA. 2024 Nov 1. doi: 10.1001/jama.2024.22056.
    PubMed    
    
    
    October 2024
26. MORCH LS, Meaidi A, Corn G, Hargreave M, et al
    Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems.
    JAMA. 2024 Oct 16. doi: 10.1001/jama.2024.18575.
    PubMed    
    
    
    September 2024
27. THORAT MA, Cuzick J, Chan AT
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15497.
    PubMed    
    
    
    
28. PETRELLI F, Ghidini A
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15491.
    PubMed    
    
    
    
29. LI C, He J, Liang W
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15488.
    PubMed    
    
    
    
30. SUN R, Wei LJ
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15494.
    PubMed    
    
    
    
31. CHEN WY, Ballman KV, Holmes MD
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer-Reply.
    JAMA. 2024 Sep 5. doi: 10.1001/jama.2024.15500.
    PubMed    
    
    
    
32. RYAN CE, Fasaye GA, Gallanis AF, Gamble LA, et al
    Germline CDH1 Variants and Lifetime Cancer Risk.
    JAMA. 2024;332:722-729.
    PubMed     Abstract available
    
    
    August 2024
33. HARRIS E
    More Data About Risks, Benefits Might Change Breast Cancer Screening Choice.
    JAMA. 2024 Aug 2. doi: 10.1001/jama.2024.13777.
    PubMed    
    
    
    July 2024
34. LEON-FERRE RA, Salgado R, Jonas SF
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer-Reply.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10483.
    PubMed    
    
    
    
35. TU H, Zhang Y, You Z
    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer.
    JAMA. 2024 Jul 3. doi: 10.1001/jama.2024.10480.
    PubMed    
    
    
    June 2024
36. RUBIN R
    Despite New Recommendations, the Debate Over Mammography Guidelines Continues.
    JAMA. 2024;331:1877-1879.
    PubMed    
    
    
    May 2024
37. MANSON JE, Crandall CJ, Rossouw JE, Chlebowski RT, et al
    The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
    JAMA. 2024;331:1748-1760.
    PubMed     Abstract available
    
    
    
38. MANDELBLATT JS, Mainor C, Hudson BI
    The Aspirin Conundrum-Navigating Negative Results, Age, Aging Dynamics, and Equity.
    JAMA. 2024;331:1709-1711.
    PubMed    
    
    
    
39. HARRIS E
    Young Patients Without Genetic Risk Have Low Chance of Second Breast Cancer.
    JAMA. 2024 May 3. doi: 10.1001/jama.2024.6734.
    PubMed    
    
    
    April 2024
40. TRENTHAM-DIETZ A, Chapman CH, Jayasekera J, Lowry KP, et al
    Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.24766.
    PubMed     Abstract available
    
    
    
41. NICHOLSON WK, Silverstein M, Wong JB, Barry MJ, et al
    Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5534.
    PubMed     Abstract available
    
    
    
42. HENDERSON JT, Webber EM, Weyrich MS, Miller M, et al
    Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.25844.
    PubMed     Abstract available
    
    
    
43. 
    Screening for Breast Cancer.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5535.
    PubMed    
    
    
    
44. ELMORE JG, Lee CI
    Toward More Equitable Breast Cancer Outcomes.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.6052.
    PubMed    
    
    
    
45. CHEN WY, Ballman KV, Partridge AH, Hahn OM, et al
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
    JAMA. 2024 Apr 29:e244840. doi: 10.1001/jama.2024.4840.
    PubMed     Abstract available
    
    
    
46. CASWELL-JIN JL, Kurian AW, Plevritis SK
    US Breast Cancer Mortality-Reply.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5482.
    PubMed    
    
    
    
47. JATOI I
    US Breast Cancer Mortality.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5479.
    PubMed    
    
    
    
48. NAROD SA
    Breast Cancer and Pregnancy in Young BRCA Carriers.
    JAMA. 2024;331:1233-1234.
    PubMed    
    
    
    
49. BLONDEAUX E, Partridge AH, Lambertini M
    Breast Cancer and Pregnancy in Young BRCA Carriers-Reply.
    JAMA. 2024;331:1234.
    PubMed    
    
    
    
50. LEON-FERRE RA, Jonas SF, Salgado R, Loi S, et al
    Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    JAMA. 2024;331:1135-1144.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum